Tissue Acquisition, Pathology and Clinical Data

组织采集、病理学和临床数据

• 批准号: 7742548
• 负责人: Othon Iliopoulos
• 金额: $ 52.87万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7742548
• 关键词: Arts; Biological Assay; Biopsy; Biostatistics Core; Blood; Blood specimen; Boston; Cancer Center; Cancer Patient; Clear Cell; Clinical; Clinical Data; Collection; Computer-Assisted Image Analysis; Confidentiality of Patient Information; Consent; DNA; Dana-Farber Cancer Institute; Data; Data Analyses; Data Collection; Databases; Equipment and supply inventories; Evaluation; Fluorescent in Situ Hybridization; Freezing; General Hospitals; Generations; Goals; Histology; Hospitals; Immunohistochemistry; In Situ Hybridization; Individual; Informatics; Institution; Israel; Kidney; Kidney Neoplasms; Laboratories; Link; Maintenance; Massachusetts; Medical center; Methylation; Microdissection; Molecular; Mutation; Nephrectomy; Outcome; Pathology; Patients; Pediatric Hospitals; Preparation; Procedures; Process; Protocols documentation; Quality Control; RNA; Renal Cell Carcinoma; Renal carcinoma; Reproduction spores; Research Personnel; Research Project Grants; Resources; Sampling; Secure; Services; Specimen; System; Tissue Banking; Tissue Banks; Tissue Microarray; Tissues; Tumor Tissue; Urine; VHL gene; Woman; data management; molecular pathology; repository; sample collection; tissue fixing

The Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core has several purposes, the first and foremost of which is to maintain a tissue, blood, and urine repository for the various investigators participating in this SPORE. This task involves the collection, freezing and storage of kidney cancer and paired normal kidney tissues as well as blood and urine from consenting RCC patients. As of July 2008, frozen tissue is available on 643 patients. In addition, 1088 patients have at least one blood sample and 741 patients have at least one urine sample stored in the specimen repository. The TAPCD Core is also responsible for the maintenance of a clinical database on all consenting kidney cancer patients. This database as well as the specimen tracking and secured data management systems provide an informatics link throughout the participating DF/HCC hospitals which allow for the sharing of clinical outcome data among SPORE investigators. The TAPCD Core also provides state-of-the-art histology and molecular pathology services to SPORE Investigators. These services include: routine histology, histopathological evaluation, immunohistochemistry, in situ hybridization, computer-assisted image analysis, and generation and interrogation of tissue microarrays. In addition, this Core performs tissue microdissection, and DNA and RNA preparation for molecular studies. Finally, the TAPCD Core is responsible for performing mutation and methylation analysis of the VHL gene in clear cell RCC specimens stored in the SPORE tissue bank. Finally, the TAPCD Core collaborates with the Biostatistics Core in data analysis and auditing. This arrangement facilitates the analysis of clinical data from kidney cancer patients consented to our protocols and the correlation of clinical data with results from the various laboratory assays being carried out as part of individual SPORE Projects.

组织获取，病理和临床数据（TAPCD）核心有几个目的 其中最重要的是为各个研究人员维持组织，血液和尿液储存库 参加这孢子。这项任务涉及肾脏癌的收集，冻结和存储 配对正常的肾脏组织以及同意RCC患者的血液和尿液。截至2008年7月， 643例患者可提供冷冻组织。此外，1088例患者至少有1个血液样本和741例 患者至少有一个存储在标本存储库中的尿液样本。 TAPCD核心还负责在所有同意肾脏上维护临床数据库 癌症患者。该数据库以及标本跟踪和安全数据管理系统 在参与的DF/HCC医院中提供信息学链接，该链接允许共享 孢子研究者之间的临床结果数据。 TAPCD核心还为孢子提供最新的组织学和分子病理学服务 调查人员。这些服务包括：常规组织学，组织病理学评估，免疫组织化学， 原位杂交，计算机辅助的图像分析以及组织的产生和询问 微阵列。此外，该核心进行组织显微解剖，DNA和RNA制备 分子研究。最后，TAPCD核心负责执行突变和甲基化分析 在孢子组织库中存储的透明细胞RCC标本中的VHL基因的。 最后，TAPCD核心在数据分析和审计中与生物统计学核心合作。这 安排有助于分析我们同意我们方案的肾癌患者的临床数据 以及临床数据的相关性与作为各种实验室测定的结果作为作为一部分的一部分进行的结果 个别孢子项目。